Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Pediatrix Medical Group (MD)
NYSE:MD
Holding MD?
Track your performance easily
Earnings Data
Report Date
Feb 13, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
0.37Last Year’s EPS
0.32Same Quarter Last Year
Moderate Buy
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 01, 2018
|% Change Since: 12.34%
|Next Earnings Date:Aug 02, 2018
Earnings Call Sentiment|Neutral
The earnings call presented a company undergoing significant operational changes with modest revenue growth and successful completion of strategic initiatives like the hybrid revenue cycle management transition. However, the impact of portfolio restructuring and increased G&A expenses present challenges. The sentiment is balanced between strategic progress and operational hurdles.Company Guidance
During the third quarter of 2024 earnings call for Pediatrix, the company provided guidance indicating a narrowed full-year adjusted EBITDA expectation of $205 million to $215 million. The quarter saw modestly ahead-of-expectation results fueled by same-unit revenue growth and stable to positive patient volumes across core service lines. The company has completed its transition to a hybrid revenue cycle management structure without disrupting operating results and is focused on a portfolio restructuring plan that involves exiting businesses worth $200 million in revenue, aiming for a $30 million annualized improvement in adjusted EBITDA. The restructuring plan is expected to complete by the end of the fourth quarter, with a portion of benefits realized in 2024 and the remainder in 2025 and beyond. Additionally, the company generated $96 million in operating cash flow during the quarter, ending with a cash balance of just over $100 million, reducing net debt to $515 million, equating to a net leverage of just under 2.5x based on the adjusted EBITDA outlook.Modest Revenue Growth
Third quarter operating results were modestly ahead of expectations, driven primarily by same-unit revenue growth and stable to positive patient volumes across all core service lines.
Successful Transition to Hybrid Revenue Cycle Management
The company completed the final wave of its transition to a hybrid revenue cycle management structure without any material disruption to operating results.
Strong Cash Flow Generation
Generated $96 million in operating cash flow during the third quarter compared to $81 million in the prior year.
Debt Reduction
Reduced net debt to $515 million from $600 million at June 30, reflecting net leverage of just under 2.5x based on the midpoint of the adjusted EBITDA outlook.
---
MD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
MD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 01, 2024 | $12.32 | $15.21 | +23.46% |
| Aug 06, 2024 | $7.62 | $8.97 | +17.72% |
| May 07, 2024 | $9.28 | $9.05 | -2.48% |
| Feb 20, 2024 | $9.29 | $8.46 | -8.93% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Pediatrix Medical Group (MD) report earnings?
Pediatrix Medical Group (MD) is schdueled to report earning on Feb 13, 2025, TBA Not Confirmed.
What is Pediatrix Medical Group (MD) earnings time?
Pediatrix Medical Group (MD) earnings time is at Feb 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MD EPS forecast?
MD EPS forecast for the fiscal quarter 2024 (Q4) is 0.37.
---